Scarica l'app Stockscreener
3.69
3.40%
-0.13
Precedente Chiudi:
$3.82
Aprire:
$3.81
Volume 24 ore:
6,682
Relative Volume:
0.06
Capitalizzazione di mercato:
$227.64M
Reddito:
-
Utile/perdita netta:
$-66.86M
Rapporto P/E:
-3.075
EPS:
-1.2
Flusso di cassa netto:
$-58.82M
1 W Prestazione:
-1.34%
1M Prestazione:
-4.90%
6M Prestazione:
-40.96%
1 anno Prestazione:
+10.15%
Intervallo 1D:
$3.67
$3.81
Intervallo di 1 settimana:
$3.645
$4.205
Portata 52W:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Confronta DSGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
3.69 | 227.64M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.07 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.47 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.10 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.37 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-06-10 | Iniziato | Wedbush | Outperform |
| 2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-19 | Iniziato | Goldman | Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-20 | Iniziato | Piper Sandler | Overweight |
| 2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Design Therapeutics Confirms Directors at Annual Meeting - TipRanks
Design Therapeutics reports voting results from annual meeting - Investing.com
Squarepoint Ops LLC Has $297,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa
Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com Australia
RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com - Investing.com South Africa
Design Therapeutics (DSGN) Advances Friedreich Ataxia Clinical T - GuruFocus
Design Therapeutics starts Friedreich ataxia patient trial - Investing.com
Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2 - marketscreener.com
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - The Manila Times
Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application - Nasdaq
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Bank of America Corp DE Sells 556,157 Shares of Aegon Ltd. (NYSE:AEG) - Defense World
40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - TradingView
Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation - Stock Titan
Autodesk (NASDAQ:ADSK) Price Target Raised to $376.00 at Citigroup - Defense World
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail
Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News
Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times
Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World
FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail
Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com
Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale - Morningstar
Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com
Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times
Design Therapeutics, Inc. SEC 10-Q Report - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Design Therapeutics Inc Azioni (DSGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| William Arsani | Director |
Aug 09 '24 |
Sale |
4.25 |
814,874 |
3,463,214 |
0 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):